Viking Therapeutics rose 42% after VK2735 data showed patients maintained up to 97% of prior weight loss with every-other-week dosing and about 90% with monthly dosing. The update highlights dosing flexibility as VK2735 heads toward Phase 3, with no plateau seen by week 33.
published
Viking Therapeutics rose 42% after VK2735 data showed patients maintained up to 97% of prior weight loss with every-other-week dosing and about 90% with monthly dosing. The update highlights dosing flexibility as VK2735 heads toward Phase 3, with no plateau se
Latest documented BWB result
$APP market result
Exit $APP Sold Puts for a nice profit and then sold more Puts - this time the $325's for $3.97
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.